乳癌核心針活體組織切片市場 - 全球產業規模、佔有率、趨勢、機會和預測，按技術、最終用途和地區、競爭細分，2019-2029F

2023 年，全球乳癌核心針切片市場估值為8 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為8.90%。用於提取組織的醫療程序從乳房樣本進行徹底的分析和診斷。它是一種微創技術，用於確定乳房異常的惡性或良性，特別是在乳房 X 光檢查、超音波或 MRI 掃描發現可疑結果後。與手術活體組織切片相比，空心針活體組織切片涉及更小的切口或穿刺，從而減少組織創傷並加快恢復時間。這些活體組織切片提供了對於準確的病理檢查至關重要的組織樣本，有助於精確表徵乳房異常。鑑於乳癌作為健康問題的全球重要性，對諸如空心針活體組織切片等精確有效的診斷程序的需求不斷成長。對早期發現的重視強調了定期篩檢和及時診斷的重要性，進一步凸顯了空心針活體組織切片在促進及時、準確診斷方面的作用。成像技術的進步提高了對可疑病變的檢測，推動了對空心針活體組織切片以確認其性質的需求。

市場概況
預測期	2025-2029
2023 年市場規模	8億美元
2029 年市場規模	13.4億美元
2024-2029 年複合年成長率	8.90%
成長最快的細分市場	基於 MRI 的乳房活體組織切片
最大的市場	北美洲

此外，隨著腫瘤學向個人化醫療和標靶治療的轉變，芯針活體組織切片促進的精確腫瘤表徵變得越來越重要。公眾宣傳活動和有組織的乳癌篩檢計畫等措施鼓勵女性接受常規篩檢，從而提高檢出率並增加對活體組織切片程序的需求。

主要市場促進因素

技術創新

老年人口不斷增加

篩檢和宣傳活動

主要市場挑戰

費用和報銷問題

診斷準確性和誤報/陰性

主要市場趨勢

偏好微創手術

細分市場洞察

技術洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：COVID-19 對全球乳癌核心針切片市場的影響

第 5 章：客戶之聲

第 6 章：全球乳癌核心針切片市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按技術分類（基於 MRI 的乳房切片檢查、基於超音波的乳房切片檢查、基於乳房 X 光攝影（立體定位）的乳房切片檢查、基於 CT 的乳房切片檢查、其他基於影像的乳房切片檢查）
  • 按最終用途（醫院和診斷實驗室、製藥和生物技術公司、學術和研究機構）
  • 按地區
  • 按公司分類 (2023)
• 市場地圖

第 7 章：亞太地區乳癌核心針切片市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依技術
  • 按最終用途
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 8 章：歐洲乳癌核心針切片市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依技術
  • 按最終用途
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 9 章：北美乳癌核心針切片市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依技術
  • 按最終用途
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第 10 章：南美洲乳癌核心針切片市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依技術
  • 按最終用途
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 11 章：中東和非洲乳癌核心針活體組織切片市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依技術
  • 按最終用途
  • 按國家/地區
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 12 章：市場動態

• 促進要素
• 挑戰

第 13 章：市場趨勢與發展

• 最近的發展
• 產品發布
• 併購

第 14 章：全球乳癌核心針切片市場：SWOT 分析

第 15 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第 16 章：大環境分析

第17章：競爭格局

• Intact Medical Corporation
• Ethicon Endo Surgery
• Galini SRL
• Leica Biosystems Nussloch GmbH
• Hologic Inc.
• Argon Medical Devices
• Encapsule Medical Devices LLC.
• Cook Medical Incorporated
• Becton & Dickinson Company
• CR Bard, Inc

第 18 章：策略建議

第19章調查會社について,免責事項

Global Breast Cancer Core Needle Biopsy Market was valued at USD 0.80 billion in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.90% through 2029. A Breast Cancer Core Needle Biopsy is a medical procedure utilized for extracting tissue samples from the breast to conduct thorough analysis and diagnosis. It serves as a minimally invasive technique for determining the malignancy or benignity of breast anomalies, particularly following suspicious findings on mammograms, ultrasounds, or MRI scans. Compared to surgical biopsies, core needle biopsies involve smaller incisions or punctures, resulting in reduced tissue trauma and quicker recovery times. These biopsies provide tissue samples crucial for accurate pathological examination, aiding in the precise characterization of breast abnormalities. Given the global significance of breast cancer as a health concern, there is a growing demand for precise and efficient diagnostic procedures like core needle biopsies. The emphasis on early detection underscores the importance of regular screenings and prompt diagnosis, further highlighting the role of core needle biopsies in facilitating timely and accurate diagnosis. Advancements in imaging technologies have improved the detection of suspicious lesions, driving the need for core needle biopsies to confirm their nature.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 0.80 Billion
Market Size 2029	USD 1.34 Billion
CAGR 2024-2029	8.90%
Fastest Growing Segment	MRI-Based Breast Biopsy
Largest Market	North America

Also, with the shift towards personalized medicine and targeted therapies in oncology, precise tumor characterization facilitated by core needle biopsies is increasingly crucial. Initiatives such as public awareness campaigns and organized breast cancer screening programs encourage women to undergo routine screenings, resulting in higher detection rates and an increased demand for biopsy procedures.

Key Market Drivers

Technological Innovations

Advancements in imaging technologies such as ultrasound, mammography, and MRI have significantly improved the accuracy of image-guided core needle biopsies. Real-time imaging enables precise guidance of the biopsy needle to the target area, enhancing tissue sampling accuracy. Digital breast tomosynthesis, or 3D mammography, offers clearer and more detailed breast tissue images, aiding in biopsy accuracy through multiple views from different angles. Robotic-assisted biopsy systems provide heightened precision and control, minimizing variability from human factors and improving sampling accuracy. Vacuum-assisted biopsy (VAB) systems use vacuum pressure to gently draw tissue into the biopsy needle, enhancing efficiency and diagnostic yield. Non-invasive localization systems, enabled by wireless technology, assist surgeons in precisely locating and removing marked breast lesions post-biopsy. Integrated software tools with imaging systems aid in planning biopsy paths, calculating needle trajectory, and optimizing sample collection, resulting in more accurate and efficient biopsies. Dual-Energy Contrast-Enhanced Digital Mammography combines contrast-enhanced mammography with 3D imaging, facilitating better visualization of cancer-associated abnormal blood vessels and guiding more accurate biopsies.

Specialized biopsy devices designed for MRI-guided biopsies are crafted from non-magnetic materials, ensuring compatibility with MRI scanners. Liquid biopsies, though not traditional core needle biopsies, involve analyzing blood samples for circulating tumor DNA (ctDNA) or biomarkers, offering genetic tumor insights without tissue sampling. Artificial Intelligence (AI) and Machine Learning enhance medical image analysis, aiding in identifying subtle abnormalities and assisting in biopsy path planning and lesion nature prediction. Needle design innovations prioritize reduced tissue damage, improved accuracy, and patient comfort. Features like self-contained spring-loaded needles and beveled-tip designs, equipped with sensors for real-time feedback on tissue stiffness and proximity to critical structures, elevate sampling precision. These advancements collectively contribute to the growth of the Global Breast Cancer Core Needle Biopsy Market.

Growing Geriatric Population

As the population ages, the occurrence of various health conditions, including breast cancer, tends to rise. Breast cancer risk escalates with age, particularly among the elderly population, necessitating more frequent screenings and diagnostic procedures like core needle biopsies. Older individuals face a heightened risk of delayed diagnosis, often stemming from factors such as reduced participation in screening programs. Such delays may lead to the requirement for more invasive diagnostic measures like core needle biopsies. Elderly patients commonly present with comorbidities and complex medical backgrounds, complicating treatment decisions. Core needle biopsies offer crucial insights into tumor characteristics, facilitating appropriate treatment planning. Tailored treatment plans, considering factors like overall health, medical history, and cancer aggressiveness, are often necessary for older patients, and core needle biopsies play a pivotal role in providing the requisite information.

Core needle biopsies are generally less invasive with shorter recovery periods compared to surgical biopsies, a significant advantage for older patients with potentially diminished physical resilience. Breast cancer screening guidelines advocate regular mammograms for specific age groups of women. As women age, the likelihood of requiring further evaluation via core needle biopsies due to suspicious mammogram findings rises. With advancements in healthcare and quality of life, many seniors are living longer, making timely detection and diagnosis of breast cancer increasingly critical for maintaining quality of life. Early detection significantly enhances treatment outcomes, especially considering the heightened risk of aggressive tumors among the geriatric population. As the demand for geriatric healthcare services surges, facilities specializing in elderly care are more inclined to provide comprehensive diagnostic services, including core needle biopsies. Public health campaigns targeting breast cancer awareness among the elderly encourage participation in screenings and diagnostic procedures, further fueling demand for the Global Breast Cancer Core Needle Biopsy Market.

Screening and Awareness Campaigns

These campaigns are designed to educate the public about breast cancer detection, promote regular screenings, and advocate for early diagnosis. By highlighting the importance of early detection in improving breast cancer outcomes, they stimulate demand for diagnostic procedures like core needle biopsies. Encouraging individuals, especially those at higher risk or in specific age groups, to undergo breast cancer screenings leads to increased detection of suspicious lesions requiring further evaluation through core needle biopsies. Routine screenings, such as mammograms, often reveal abnormalities requiring additional testing, potentially resulting in core needle biopsy recommendations to determine the nature of the abnormality.

Awareness campaigns play a vital role in educating individuals about the diagnostic process, including core needle biopsies, to alleviate concerns and promote acceptance of the procedure. Targeting specific demographics, such as particular age groups or high-risk populations, ensures that those who would benefit most from core needle biopsies understand their importance. Promoting routine health check-ups, during which healthcare providers may recommend screenings and subsequent diagnostic procedures like core needle biopsies, is a key aspect of these campaigns.

Empowering individuals with knowledge about their healthcare options encourages proactive behavior, such as requesting necessary diagnostic procedures. Successful awareness campaigns lead to more early-stage breast cancer diagnoses, potentially reducing breast cancer mortality rates. Community events, workshops, and support groups organized as part of these campaigns create a sense of community and encourage individuals to prioritize their health, including undergoing necessary diagnostic procedures. This dynamic contributes to the increasing demand in the Global Breast Cancer Core Needle Biopsy Market.

Key Market Challenges

Cost and Reimbursement Issues

These challenges can impact both healthcare providers and patients, affecting the adoption and accessibility of core needle biopsy procedures. Healthcare facilities need to invest in specialized equipment, imaging technologies, and trained personnel to offer core needle biopsies. The initial investment required for these resources can be substantial. Core needle biopsies involve various costs, including equipment maintenance, consumables, imaging guidance, and pathology analysis. These costs can contribute to the overall expenses of the procedure. Healthcare providers often rely on reimbursements from insurance companies or government programs to cover the costs of medical procedures. Inadequate reimbursement rates for core needle biopsies might discourage providers from offering these services. Reimbursement policies can vary based on factors such as the specific procedure, facility type, geographical region, and insurance coverage. This variability can lead to uncertainty for both providers and patients. In some cases, insurance plans might not cover the full cost of core needle biopsies or might not cover them at all. This financial burden can discourage patients from undergoing the procedure. Healthcare providers often need to go through pre-authorization processes, submitting detailed documentation to insurance companies to demonstrate the medical necessity of the procedure. This administrative burden can delay patient care. Patients may be required to cover a portion of the procedure's cost through co-pays, deductibles, or other out-of-pocket expenses. High out-of-pocket costs might deter patients from choosing core needle biopsies.

Diagnostic Accuracy and False Positives/Negatives

Accurate diagnostic results from core needle biopsies are essential for determining the nature of breast lesions. Oncologists rely on these results to formulate effective treatment plans tailored to each patient's condition. False positives (incorrectly identifying cancer) and false negatives (missing cancer) can lead to inappropriate or delayed treatment decisions. Accurate biopsy results are essential for choosing the most suitable treatment strategy. False-positive results can lead to unnecessary anxiety and stress for patients, while false negatives might lead to delayed diagnosis and treatment, negatively affecting patient outcomes and mental well-being. In cases of inconclusive or inaccurate core needle biopsy results, patients might need to undergo rebiopsy or additional diagnostic procedures, increasing healthcare costs and patient discomfort. Incorrect diagnoses can strain healthcare resources by requiring additional medical interventions and treatments that could have been avoided with accurate initial diagnoses. Healthcare providers need to implement quality control and assurance measures to minimize the risk of false results. Ensuring consistent accuracy across different facilities and professionals can be challenging. Accurate interpretation of core needle biopsy samples requires skilled pathologists who can differentiate between various breast tissue abnormalities. Ensuring enough skilled pathologists is essential.

Key Market Trends

Preference for Minimally Invasive Procedures

Minimally invasive procedures involve smaller incisions or needle insertions, leading to less tissue trauma and reduced post-procedure discomfort and pain. Patients are more likely to choose core needle biopsies over surgical options due to the associated comfort. Minimally invasive procedures typically result in quicker recovery times compared to traditional surgeries. This is especially beneficial for patients who wish to return to their daily activities as soon as possible. Many minimally invasive core needle biopsies can be performed on an outpatient basis. This convenience allows patients to undergo the procedure and return home on the same day, reducing the need for hospitalization. Minimally invasive techniques usually carry a lower risk of infection, bleeding, and other complications commonly associated with more invasive surgical procedures. Minimally invasive procedures often leave smaller scars or no visible scars, which can be important for patients concerned about cosmetic outcomes. Core needle biopsies are often performed under local anesthesia, reducing the risks associated with general anesthesia and allowing patients to remain awake and comfortable during the procedure. The preference for minimally invasive procedures aligns with patients' desire for less invasive approaches to healthcare. Patients are more likely to agree to recommended procedures when they are perceived as less invasive. Minimally invasive core needle biopsies can be performed in a variety of medical settings, including clinics and outpatient centers, making them more accessible to a broader patient population.

Segmental Insights

Technology Insights

In 2023, the Global Breast Cancer Core Needle Biopsy Market dominated by MRI-Based Breast Biopsy segment in the forecast period and is predicted to continue expanding over the coming years. MRI (Magnetic Resonance Imaging) offers high-resolution images of breast tissue, making it highly accurate in identifying suspicious lesions or abnormalities. This accuracy is crucial for guiding the biopsy needle to the precise location of the abnormality, which enhances the diagnostic yield of the biopsy. MRI is particularly effective in detecting and characterizing complex breast lesions that might be difficult to visualize using other imaging modalities. This makes it a valuable tool for identifying lesions that require further investigation through biopsy. For individuals with a high risk of breast cancer due to family history or genetic mutations (e.g., BRCA1/BRCA2), MRI-based screening and biopsies can offer better sensitivity in detecting early-stage cancers or precancerous lesions.

Regional Insights

The North America region dominates the Global Breast Cancer Core Needle Biopsy Market in 2023. North America, particularly the United States and Canada, has a well-developed and advanced healthcare infrastructure. This includes state-of-the-art medical facilities, research institutions, and a robust regulatory environment that fosters innovation and rapid adoption of new medical technologies. The region has a history of early adoption of advanced medical technologies. This includes diagnostic tools and procedures like breast cancer core needle biopsies. Healthcare providers in North America are often quick to embrace new techniques that can enhance patient care and outcomes. Many leading medical device manufacturers and biotechnology companies are based in North America. This concentration of research and development efforts contributes to the creation of innovative biopsy devices and techniques that attract global attention. North America places a significant emphasis on cancer screening, early detection, and diagnosis. This focus drives the demand for accurate and minimally invasive diagnostic procedures like core needle biopsies.

Key Market Players

Intact Medical Corporation

Ethicon Endo Surgery

Galini SRL

Leica Biosystems Nussloch GmbH

Hologic Inc.

Argon Medical Devices

Encapsule Medical Devices LLC.

Cook Medical Incorporated

Becton & Dickinson Company

C.R. Bard, Inc.

Report Scope:

In this report, the Global Breast Cancer Core Needle Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Core Needle Biopsy Market, By Technology:

MRI-Based Breast Biopsy Ultrasound-Based Breast Biopsy Mammography-Based (Stereotactic) Breast Biopsy CT-Based Breast Biopsy Other Image Based Breast Biopsy

Breast Cancer Core Needle Biopsy Market, By End-user:

Hospitals & Diagnostic Laboratories Pharmaceutical & Biotechnology companies Academic & Research Institutes

Breast Cancer Core Needle Biopsy Market, By region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

South Korea

Australia

Japan

Europe

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Breast Cancer Core Needle Biopsy Market.

Available Customizations:

Global Breast Cancer Core Needle Biopsy Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Breast Cancer Core Needle Biopsy Market

5. Voice of Customer

6. Global Breast Cancer Core Needle Biopsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology (MRI-Based Breast Biopsy, Ultrasound-Based Breast Biopsy, Mammography-Based (Stereotactic) Breast Biopsy, CT-Based Breast Biopsy, Other Image Based Breast Biopsy)
  • 6.2.2. By End Use (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology companies, Academic & Research Institutes)
  • 6.2.3. By Region
  • 6.2.4. By Company (2023)
• 6.3. Market Map

7. Asia Pacific Breast Cancer Core Needle Biopsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Asia Pacific: Country Analysis
  • 7.3.1. China Breast Cancer Core Needle Biopsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By End Use
  • 7.3.2. India Breast Cancer Core Needle Biopsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By End Use
  • 7.3.3. Australia Breast Cancer Core Needle Biopsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By End Use
  • 7.3.4. Japan Breast Cancer Core Needle Biopsy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By End Use
  • 7.3.5. South Korea Breast Cancer Core Needle Biopsy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By End Use

8. Europe Breast Cancer Core Needle Biopsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Breast Cancer Core Needle Biopsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By End Use
  • 8.3.2. Germany Breast Cancer Core Needle Biopsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By End Use
  • 8.3.3. Spain Breast Cancer Core Needle Biopsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By End Use
  • 8.3.4. Italy Breast Cancer Core Needle Biopsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By End Use
  • 8.3.5. United Kingdom Breast Cancer Core Needle Biopsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By End Use

9. North America Breast Cancer Core Needle Biopsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Breast Cancer Core Needle Biopsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By End Use
  • 9.3.2. Mexico Breast Cancer Core Needle Biopsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By End Use
  • 9.3.3. Canada Breast Cancer Core Needle Biopsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By End Use

10. South America Breast Cancer Core Needle Biopsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Breast Cancer Core Needle Biopsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By End Use
  • 10.3.2. Argentina Breast Cancer Core Needle Biopsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By End Use
  • 10.3.3. Colombia Breast Cancer Core Needle Biopsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By End Use

11. Middle East and Africa Breast Cancer Core Needle Biopsy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Technology
  • 11.2.2. By End Use
  • 11.2.3. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Breast Cancer Core Needle Biopsy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Technology
      • 11.3.1.2.2. By End Use
  • 11.3.2. Saudi Arabia Breast Cancer Core Needle Biopsy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Technology
      • 11.3.2.2.2. By End Use
  • 11.3.3. UAE Breast Cancer Core Needle Biopsy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Technology
      • 11.3.3.2.2. By End Use

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Global Breast Cancer Core Needle Biopsy Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

• 17.1. Intact Medical Corporation
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Financials (If Listed)
  • 17.1.4. Product & Service Offerings
  • 17.1.5. Recent Developments
  • 17.1.6. Key Personnel
  • 17.1.7. SWOT Analysis
• 17.2. Ethicon Endo Surgery
• 17.3. Galini SRL
• 17.4. Leica Biosystems Nussloch GmbH
• 17.5. Hologic Inc.
• 17.6. Argon Medical Devices
• 17.7. Encapsule Medical Devices LLC.
• 17.8. Cook Medical Incorporated
• 17.9. Becton & Dickinson Company
• 17.10.C.R. Bard, Inc

18. Strategic Recommendations

19. About Us & Disclaimer